Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?
News & Analysis: Novartis
Israeli scientists claim they have a cure for cancer. Investors' response? The proof is in the pudding.
Here’s how CAR-T therapies did in their first full year on the market.
Here's how calamities we witnessed in 2018 will hound biotech investors in the new year.
Novartis continues its pivot toward specialized medicines by acquiring Endocyte.
Wall Street is optimistic about upcoming treatment launches.
NVS earnings call for the period ending June 30, 2018.
Here's what you need to know about the M&A mania spreading through big pharma.
NVS earnings call for the period ending March 31, 2018.
$9.8 billion isn’t pocket change, but AveXis presents some huge potential opportunities down the road.